INDOCO2023-07-012023-09-30 INDOCO2023-07-012023-09-30 INDOCO2023-07-012023-09-30in-bse-fin:OneOperatingExpenses01Member INDOCO2023-07-012023-09-30in-bse-fin:OneOperatingExpenses02Member INDOCO2023-07-012023-09-30in-bse-fin:FourOperatingExpenses01Member INDOCO2023-07-012023-09-30in-bse-fin:FourOperatingExpenses02Member INDOCO2023-09-30 INDOCO2023-07-012023-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDOCO2023-07-012023-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDOCO2023-07-012023-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member INDOCO2023-07-012023-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532612 INDOCO NOTLISTED Indoco Remedies Limited Equity 2023-04-01 2024-03-31 2023-10-19 2023-10-06 INR Lakhs Half yearly 10:30:00 12:00:00 2023-10-19 2023-10-19 true Cash Flow Indirect Not applicable Single segment Pharmaceuticals 2023-07-01 2023-09-30 Unaudited Consolidated 4817300000.00 44300000.00 4861600000.00 1309400000.00 257400000.00 -93700000.00 921200000.00 81100000.00 214100000.00 1709300000.00 4398800000.00 462800000.00 0.00 462800000.00 116600000.00 -6200000.00 110400000.00 0.00 352400000.00 0.00 0.00 0.00 0.00 352400000.00 -2100000.00 350300000.00 350800000.00 1600000.00 348700000.00 1600000.00 184300000.00 2 3.82 3.82 0.00 0.00 3.82 3.82 1. The unaudited Consolidated Results for the Quarter and Half Year ended 30th September, 2023 have been reviewed by the Audit committee and approved by the Board of Director of the Company at its meeting held on 19th October, 2023. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Consolidated Financial Results. 2. The figures for corresponding previous periods have been restated/regrouped wherever necessary, to make them comparable. 3. The company has only one primary reportable segment of activity, namely Pharmaceuticals. 4. Net Sales & Income from Operations as per Secondary Segment (Geographical) is as follows: Net Sales & Qtr ended Qtr ended Qtr ended Half year ended Half year ended Year ended Income from 30.09.2023 30.06.2023 30.09.2022 30.09.2023 30.09.2022 31.03.2023 Operations (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) India 25,797 23,417 22,506 49,214 43,204 84,979 Outside India 21,561 18,264 17,989 39,825 36,812 79,026 ---------------------------------------------------------------------------------------------------------- 47,358 41,681 40,495 89,039 80,016 1,64,005 ===================================================== 5. The Consolidated Financial Results includes the results of the following Companies Name of theCompany % of shareholding Consolidated as Xtend Industrial Designers & Engineers Pvt Ltd 100.00 Subsidiary Indoco Remedies Czech S R O 100.00 Subsidiary Indoco Remedies UK Ltd 100.00 Subsidiary Warren Remedies Private Ltd 100.00 Subsidiary FPP Holding Company , LLC 85.00 Subsidiary 6. The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30.September, 2023 7. There are no exceptional items. Single segment 2023-04-01 2023-09-30 Unaudited Consolidated 9082300000.00 48400000.00 9130700000.00 2339200000.00 578700000.00 -157900000.00 1836600000.00 159100000.00 412900000.00 3160400000.00 8329000000.00 801700000.00 0.00 801700000.00 202000000.00 5600000.00 207600000.00 0.00 594100000.00 0.00 0.00 0.00 0.00 594100000.00 -4400000.00 589700000.00 594600000.00 -500000.00 590200000.00 -500000.00 184300000.00 2 6.45 6.44 0.00 0.00 6.45 6.44 Other Expenses 1451600000.00 Research & Development Expense 257700000.00 Other Expenses 2663900000.00 Research & Development Expense 496500000.00 20100000.00 6129900000.00 929600000.00 214400000.00 1006700000.00 273800000.00 14600000.00 28700000.00 44700000.00 88000000.00 762400000.00 9404800000.00 3554300000.00 30700000.00 4045100000.00 610200000.00 41600000.00 6100000.00 150000000.00 4883700000.00 1537600000.00 9975600000.00 19380400000.00 184300000.00 10499100000.00 10683400000.00 10703500000.00 2505000000.00 29100000.00 2534100000.00 320500000.00 66000000.00 73600000.00 2994200000.00 2455300000.00 1697900000.00 940800000.00 5094000000.00 139000000.00 449700000.00 5682700000.00 8676900000.00 19380400000.00 156200000.00 -294400000.00 -560700000.00 0.00 -405400000.00 -3900000.00 -30300000.00 -119300000.00 0.00 463300000.00 0.00 -57200000.00 0.00 412900000.00 0.00 -45700000.00 -19400000.00 347700000.00 53700000.00 -17200000.00 0.00 8500000.00 18000000.00 0.00 0.00 0.00 45000000.00 900000.00 0.00 -64300000.00 737400000.00 0.00 0.00 0.00 271400000.00 0.00 466000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8600000.00 1208000000.00 0.00 20700000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13600000.00 0.00 -17500000.00 0.00 -1224000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1126500000.00 -495800000.00 18000000.00 0.00 190800000.00 154600000.00 0.00 0.00 1258900000.00 500900000.00 0.00 500900000.00 109300000.00 610200000.00 Items that will not be reclassified to profit and loss -3000000.00 Items that will not be reclassified to profit and loss -6000000.00 -3000000.00 -6000000.00 -800000.00 -1500000.00 Items that may be reclassified to profit or loss 100000.00 Items that may be reclassified to profit or loss 100000.00 100000.00 100000.00 0.00 0.00